EcoDrugPlus

Tyrosine Kinase 2

Ensembl ID : ENSLCRG00005000887
Gene Symbol: TYK2
3 Cross references
195 Possible Orthologues:

Tyrosine Kinase With Immunoglobulin-Like And Egf-Like Domains 1

Ensembl ID : ENSLCRG00005010424
Gene Symbol: TIE1
3 Cross references
205 Possible Orthologues:

Urotensin 2 Receptor

Ensembl ID : ENSLCRG00005021908
Gene Symbol: UTS2R
3 Cross references
97 Possible Orthologues:

Utrophin

Ensembl ID : ENSLCRG00005011040
Gene Symbol: UTRN
3 Cross references
270 Possible Orthologues:

V-Ki-Ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog

Ensembl ID : ENSLCRG00005020263
Gene Symbol: KRAS
3 Cross references
207 Possible Orthologues:

V-Akt Murine Thymoma Viral Oncogene Homolog 2

Ensembl ID : ENSLCRG00005012318
Gene Symbol: AKT2
3 Cross references
209 Possible Orthologues:

V-Akt Murine Thymoma Viral Oncogene Homolog 3a

Ensembl ID : ENSLCRG00005004908
Gene Symbol: AKT3A
3 Cross references
203 Possible Orthologues:

V-Rel Avian Reticuloendotheliosis Viral Oncogene Homolog A

Ensembl ID : ENSLCRG00005015346
Gene Symbol: RELA
3 Cross references
199 Possible Orthologues:

V-Src Avian Sarcoma (Schmidt-Ruppin A-2) Viral Oncogene Homolog

Ensembl ID : ENSLCRG00005020425
Gene Symbol: SRC
3 Cross references
197 Possible Orthologues:

Vascular Endothelial Growth Factor Aa

Ensembl ID : ENSLCRG00005003953
Gene Symbol: VEGFAA
3 Cross references
181 Possible Orthologues:

Vascular Endothelial Growth Factor Ab

Ensembl ID : ENSLCRG00005013020
Gene Symbol: VEGFAB
3 Cross references
201 Possible Orthologues:

Vitamin D Receptor

Ensembl ID : ENSLCRG00005019954
Gene Symbol: VDR
3 Cross references
388 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).